Premium
Effect of inhaled beclomethasone dipropionate on bronchial hyperreactivity in asthmatic children during maximal allergen exposure
Author(s) -
Boner A. L.,
Piacentini G. L.,
Bonizzato C.,
Dattoli V.,
Sette L.
Publication year - 1991
Publication title -
pediatric pulmonology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.866
H-Index - 106
eISSN - 1099-0496
pISSN - 8755-6863
DOI - 10.1002/ppul.1950100102
Subject(s) - medicine , methacholine , placebo , beclometasone dipropionate , asthma , bronchial hyperreactivity , bronchial hyperresponsiveness , corticosteroid , allergen , anesthesia , inhalation , allergy , gastroenterology , respiratory disease , immunology , lung , pathology , alternative medicine
In this double blind study we evaluated the effect of a 2 months long treatment with inhaled beclomethasone dipropionate (300 μg/day) on methacholine responses in asthmatic children, during a period of maximal allergen exposure. Baseline values of methacholine PC 20 ‐FEV 1 were 0.66 ± 0.22 mg/mL (mean ± SEM) in 10 children treated with the active drug and 0.78 ± 0.21 mg/mL in 10 children treated with placebo. After 1 month of treatment PC 20 ‐FEV 1 was 1.91 ± 0.64 and 0.80 ± 0.33 mg/mL, respectively, in the groups treated with beclomethasone versus placebo. A statistically significant reduction in bronchial hyperreactivity (PC 20 ‐FEV 1 , 5.49 ± 1.86 mg/mL) but no systemic side effects were observed after 2 months of treatment with beclomethasone dipropionate. This is compared with a PC 20 ‐FEV 1 of 1.38 ± 0.52 mg/mL in the placebo group. The results confirm the effect of inhaled corticosteroids in reducing bronchial hyperreactivity, even during a period of maximal allergen exposure. Pediatr Pulmonol 1991; 10:2–5.